ATAI Investor Day Presentation Deck

RL - 007 de-risked through extensive & consistent translational data atai LIFE SCIENCES In vitro Enhanced synaptic plasticity In vivo Broad cognitive efficacy across species Predictive dose modeling Defined CNS drug exposure cognition relationship Phase 1, CSF concentration Well behaved PK confirms CNS exposures Phase 1b cognitive challenge Scopolamine challenge confirm cognition dose range Phase 2a, DPNP Showed cognitive improvements in metabolic syndrome Phase 2a, CIAS Confirmed CNS engagement and cognitive signal Consistent PK-PD relationship Confidence in active dose range Complete CMC package Excellent tolerability and safety Multiple clinical cognitive signals De-risked path forward 24

View entire presentation